2019
Pacific Edge Ltd Announces Completion of Placement
Pacific Edge Limited (NZX: PEB) is pleased to announce the successful completion of its $7m underwritten placement announced on 21 November 2019, with strong support from new and existing investors, both in New Zealand and internationally. [read more]
Pacific Edge Ltd Announces Interim FY20 Results and Capital Raising
Pacific Edge has announced half year performance and capital raising to assist the company to progress its commercial objectives. [read more]
CFO Appointment
Pacific Edge is pleased to announce the appointment of Grant Gibson as CFO, effective from 16 Dec 2019. Grant is an experienced financial executive and chartered accountant, who brings significant financial experience to the role. He was most recently Chief Financial and Operating Officer for Dunedin-based company, TracMap. [read more]
US Clinical Review Reinforces Need for Cxbladder in Hematuria Guidelines
The Journal of the American Medical Association (JAMA) has published a clinical review paper highlighting the need for safer, non-invasive and accurate diagnostic tests and procedures for the detection and management of bladder cancer that can help lower the need for CT imaging. [read more]
Urologist KOL Profiles Cxbladder
Pacific Edge (NZX:PEB) and Life Science Ventures hosted a Urology Key Opinion Leader event in New York on 18th July, featuring internationally renowned urologist and USA Key Opinion Leader Dr. Sia Daneshmand [read more]
Cxbladder Included in the Latest NCCN Bladder Cancer Guidelines in the USA
Cancer diagnostics company, Pacific Edge (NZX: PEB), advises that Cxbladder has been included in the latest version of the National Comprehensive Cancer Network (NCCN) Guidelines for Bladder Cancer in the USA [read more]
Clinical Study Supports Adoption of Cxbladder into New Clinical Pathway
The latest published clinical paper for Pacific Edge’s Cxbladder bladder cancer tests reveals the cementing evidence behind the introduction of new guidelines for the assessment of haematuriaby one of New Zealand’s largest public healthcare providers, Canterbury District Health Board (DHB). [read more]
Pacific Edge Reports Continued Growth in FY19
Cancer diagnostics company, Pacific Edge (NZX: PEB) has today released its audited financial results for the year ended 31 March 2019, reporting accelerating demand from new and existing customers in the second half of the financial year, particularly from New Zealand customers in the final quarter of the year. [read more]
International Urology Experts Present on Cxbladder
Pacific Edge Limited (NZX: PEB) is hosting an event today in Auckland, with two internationally renowned urologists presenting on the performance and commercial use of Cxbladder in their USA and New Zealand clinical settings respectively. [read more]
Further Compelling Clinical Evidence Supporting Cxbladder
Cxbladder’s recent diagnostic outperformance has been published in the number one ranked urology journal, European Urology, adding to Cxbladder’s comprehensive clinical evidence for physicians, reimbursers and healthcare providers alike. [read more]
Pacific Edge Full Year Results to be Announced 29 May 2019
Pacific Edge Limited (NZX:PEB) advises that it intends to announce its full year result for the financial year ended 31 March 2019 on Wednesday 29 May 2019, prior to 10am NZST. [read more]
Director Appointment
Pacific Edge Limited announces the appointment of John Duncan to the Board as an Independent Director [read more]
Request for Director Nominations
Pacific Edge Limited advises that the opening date for Director Nominations is Thursday 18th April 2019 and the closing date for Director Nominations is Friday 21st June 2019 [read more]
Cxbladder Adoption Roll-out Advances in New Zealand
Public Healthcare provider, Hawke’s Bay District Health Board, to roll out Cxbladder tests [read more]
Pacific Edge Successfully Completes Capital Raising
Pacific Edge Limited (NZX: PEB) advises that its Share Purchase Plan (SPP) has been successfully concluded and the offer has now closed. The issue price has been confirmed at $0.3427 per share. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.